Fortitude Family Office’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$29.9K Sell
1,243
-148
-11% -$3.87K 0.01% 408
2026
Q1
$39.1K Sell
1,391
-6,070
-81% -$162K 0.01% 277
2025
Q4
$186K Sell
7,461
-1,993
-21% -$50.3K 0.04% 147
2025
Q3
$241K Buy
9,454
+5
+0.1% +$123 0.06% 128
2025
Q2
$229K Sell
9,449
-142
-1% -$3.31K 0.08% 116
2025
Q1
$243K Sell
9,591
-3,268
-25% -$85.5K 0.09% 108
2024
Q4
$341K Sell
12,859
-904
-7% -$24.5K 0.12% 98
2024
Q3
$398K Buy
13,763
+3,914
+40% +$114K 0.16% 81
2024
Q2
$276K Sell
9,849
-215
-2% -$5.92K 0.16% 71
2024
Q1
$279K Buy
10,064
+206
+2% +$5.72K 0.19% 68
2023
Q4
$284K Buy
+9,858
New +$298K 0.21% 68

Other funds holding PFE

Fortitude Family Office's PFE Position: Q2 2026 in Review

Fortitude Family Office reduced its Pfizer (PFE) stake by 11% in Q2 2026, selling an estimated $3.87K and leaving 1,243 shares worth $29.9K. The position accounts for 0.01% of the portfolio, ranked #408.

Fortitude Family Office first reported a position in PFE in Q4 2023 and has held it in 11 quarters since. The position peaked at $398K in Q3 2024. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Fortitude Family Office held 1,243 shares of Pfizer worth $29.9K as of Q2 2026.
  • Fortitude Family Office sold 148 Pfizer shares in Q2 2026, an estimated $3.87K.
  • Pfizer made up 0.01% of Fortitude Family Office's portfolio in Q2 2026, its #408 holding.
  • Fortitude Family Office first reported a position in Pfizer in Q4 2023 and has held it in 11 quarters since.
  • Fortitude Family Office's Pfizer position peaked at $398K in Q3 2024.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.